Meta-analysis of Change in Weight and Heart Rate for Phentermine in Obesity
7
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study aimed to evaluate the change in weight and heart rate associated with the use of phentermine through meta-analysis based on the published literatures. Methods: Eight electronic databases, PubMed, EMBASE, Cochrane library, and five domestic databases were used to search the literature. Randomized controlled trials that evaluated the change in weight and heart rate with the use of phentermine compared with placebo were included in this study. The fixed-effect model weighted by the Mantel–Haenszel method was used in the meta-analysis, and the random-effects model was used when heterogeneity was present. Results: We included 12 studies comprising 677 patients. The change in weight observed with the use of phentermine (SMD=-1.37, 95% CI: -1.55, -1.19) was statistically significant compared with that observed with placebo. As per the subgroup analysis results, the change in weight by publication year, country, phentermine dosage, follow-up check was not heterogeneous. The change in heart rate observed with the use of phentermine (SMD=0.64, 95% CI: 0.35, 0.92) was significant compared with that observed with placebo. Conclusions: Weight loss and increased heart rate were confirmed in phentermine compared with placebo.
Abstract
Objectives: This study aimed to evaluate the change in weight and heart rate associated with the use of phentermine through meta-analysis based on the published literatures. Methods: Eight electronic databases, PubMed, EMBASE, Cochrane library, and five domestic databases were used to search the literature. Randomized controlled trials that evaluated the change in weight and heart rate with the use of phentermine compared with placebo were included in this study. The fixed-effect model weighted by the Mantel–Haenszel method was used in the meta-analysis, and the random-effects model was used when heterogeneity was present. Results: We included 12 studies comprising 677 patients. The change in weight observed with the use of phentermine (SMD=-1.37, 95% CI: -1.55, -1.19) was statistically significant compared with that observed with placebo. As per the subgroup analysis results, the change in weight by publication year, country, phentermine dosage, follow-up check was not heterogeneous. The change in heart rate observed with the use of phentermine (SMD=0.64, 95% CI: 0.35, 0.92) was significant compared with that observed with placebo. Conclusions: Weight loss and increased heart rate were confirmed in phentermine compared with placebo.
참고문헌 (38)
- Baretic M, "Targets for medical therapy in obesity", Dig Dis, 30(2), pp.168~172 (2012)
- The Asia-Pacific perspective. Redefining Obesity and Its Treatment, "WHO", Health Communications Austrailia Pty Limited on Behelf of the steering Committee, ~ (2000)
- Soo Young Kim, "The Definition of Obesity", Korean Journal of Family Medicine, 37(6), pp.309~309 (2016), 대한가정의학회
- "Prevalence of overweight among adults, BMI 25, age-standardized Estimates by Country"[URL]
- Kang JH, "Evaluation criteria of healthy body weight in Koreans -focus on obesity", Korean J Community Nutr, 6(3), pp.397~401 (2001)
- Artham SM, "The obesity paradox:impact of obesity on the prevalence and prognosis of cardiovascular diseases", Postgrad Med, 120(2), pp.34~41 (2008)
- Mokdad AH, "Actual causes of death in the United States, 2000", JAMA, 291(10), pp.1238~1245 (2004)
- Swinburn B, "Preventive strategies against weight gain and obesity", Obes Rev, 3(4), pp.289~301 (2002)
- Kim SM, "Treatment of obesity with drugs", J Korean Med Assoc, 47(4), pp.361~368 (2004)
- Padwal RS, "Drug treatments for obesity: orlistat, sibutramine, and rimonabant", Lancet, 369(9555), pp.71~77 (2007)
- Park YW, "Efficacy and safety of Phentermine for obese patients: a preliminary open-lael study", Korean J Obes, 14(1), pp.1~8 (2005)
- Haddock CK, "Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials", Int J Obes Relat Metab Disord, 26(2), pp.262~273 (2002)
- Smith SM, "Phentermine", topiramate for the treatment of obesity, 2013, pp.47(3), 340~349
- Stafford RS, "National trends in antiobesity medication use", Arch Intern Med, 163(9), pp.1046~1050 (2003)
- "SIGN grading system 1999-2012"[URL]
- Glass GV, "Primary, secondary, and meta-analysis of research", Educ Res, 5(10), pp.3~8 (1976)
- 이준영, "메타분석", Endocrinology and Metabolism, 23(6), pp.361~378 (2008), 대한내분비학회
- Oxman AD, "A consumer’s guide to subgroup analyses", Ann Intern Med, 116(1), pp.78~84 (1992)
- Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315(7109), pp.629~634 (1997)
- 심성률, "중재 메타분석을 위한 STATA 명령어", 보건정보통계학회지, 41(1), pp.123~134 (2016), 한국보건정보통계학회[DOI]
- Brightwell DR, "Effects of a combined behavioral and pharmacological program on weight loss", Int J Obes, 3(2), pp.141~148 (1979)
- Karason K, "Heart rate variability in obesity and the effect of weight loss", Am J Cardiol, 83(8), pp.1242~1247 (1999)
- Douglas A, "Plasma phentermine levels, weight loss and side-effects", Int J Obes, 7(6), pp.591~595 (1983)
- Pasquali R, "Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects", Clin Sci, 82(1), pp.85~92 (1992)
- Gaasch WH, "Valvular heart disease induced by anorectic drugs", UpToDate, 8(3) (2000)
- Khera R, "Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis", JAMA, 315(22), pp.2424~2434 (2016)
- Derosa G, "Anti-obesity drugs: a review about their effects and their safety", Expert Opin Drug Saf, 11(3), pp.459~471 (2012)
- Cheung BM, "Safety of antiobesity drugs", Ther Adv Drug Saf, 4(4), pp.171~181 (2013)
- Truant AP, "Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study", Curr Ther Res Clin Exp, 14(11), pp.726~738 (1972)
- Choi CJ, "Double-blind, parallelgroup, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients", Korean J Obe, 14(3), pp.155~162 (2005)
- 김경곤, "Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People", Yonsei Medical Journal, 47(5), pp.614~625 (2006), 연세대학교의과대학
- Kang JG, "Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity", Diabetes Obes Metab, 12(10), pp.876~882 (2010)
- Hendricks EJ, "Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity", Obes, 19(12), pp.2351~2360 (2011)
- Weintraub M, "A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination", Arch Iinter Med, 144(6), pp.1143~1148 (1984)
- Moldovan CP, "Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings", Obes, 24(11), pp.2344~2350 (2016)
- Langlois KJ, "A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity", Curr Ther Res Clin Exp, 16(4), pp.289~296 (1974)
- 방우대, "Pulmonary Hypertension Associated with Use of Phentermine", Yonsei Medical Journal, 51(6), pp.971~973 (2010), 연세대학교의과대학